Drug Database
Back to search

Poland· PL-100196490

Abseamed

A erythropoietin product containing epoetinum alfa, registered in Poland by Medice Arzneimittel Puetter GmbH & Co. KG. The same ATC class is registered in 12 of our 19 countries.

ATC B03XA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAbseamedATCB03XA01REGISTER NO.PL-100196490PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about epoetinum alfaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Erythropoietin is registered in 12 of 19 countries.

Countries holding a registration under ATC B03XA01 (erythropoietin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search erythropoietin products by name

Erythropoietin · ATC B03XA01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Epoetinum alfa
Manufacturer
Medice Arzneimittel Puetter GmbH & Co. KG
Country
Poland (PL)
ATC code
B03XA01
ATC class
Erythropoietin
Defined daily dose
1 TSD, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990654154
  • gtin
    05909990654161

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for erythropoietin.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check erythropoietin against other medicinesHow interaction checks work

Erythropoietin · interactions on record

18 records

  • 5 severe
  • 3 moderate
  • 10 minor

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Erythropoietin in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All erythropoietin products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Erypo
  • Belgium · Eprex
  • Czechia · Eprex
  • Germany · Erypo Fs
  • Spain · Eprex
  • France · Eprex
  • United Kingdom (Northern Ireland) · Eprex
  • Greece · Eprex
  • Iceland · Abseamed, Binocrit
  • Italy · Eprex
  • Liechtenstein · Binocrit, Epoetin Alfa Hexal
  • Luxembourg · Eprex
  • Netherlands · Eprex
  • Norway · Abseamed, Binocrit
  • Portugal · Eprex
  • Slovenia · Eprex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a9c36487-b57c-4c5d-b446-8c39d3610be4
GET /v1/drugs/a9c36487-b57c-4c5d-b446-8c39d3610be4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "6000 j.m./0,6 ml",
  "packaging": "05909990654154 ¦ Rpz ¦ EU/1/07/412/011 ¦ 44528\n1 amp.-strzyk. 6000 j.m. /0,6 ml\n05909990654161 ¦ Rpz ¦ EU/1/07/412/012 ¦ 44529\n6 amp.-strzyk. 6000 j.m. /0,6 ml\nRpz ¦ EU/1/07/412/037 ¦ 88115\n1 amp.-strzyk. \nRpz ¦ EU/1/07/412/038 ¦ 88116\n6 amp.-strzyk.",
  "substance": "Epoetinum alfa 6000 j.m./0,6 ml",
  "common_name": "Epoetinum alfa",
  "pl_product_id": "100196490",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about erythropoietin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console